Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

Authors :: van de Loosdrecht AA
Ireland R
Kern W
Della Porta MG
Alhan C
Balleisen JS
Bettelheim P
Bowen DT
Burbury K
Eidenschink L
Cazzola M
Chu SS
Cullen M
Cutler JA
Dräger AM
Feuillard J
Fenaux P
Font P
Germing U
Haase D
Hellström-Lindberg E
Johansson U
Kordasti S
Loken MR
Malcovati L
te Marvelde JG
Matarraz S
Milne T
Moshaver B
Mufti GJ
Nikolova V
Ogata K
Oelschlaegel U
Orfao A
Ossenkoppele GJ
Porwit A
Platzbecker U
Preijers F
Psarra K
Richards SJ
Subirá D
Seymour JF
Tindell V
Vallespi T
Valent P
van der Velden VH
Wells DA
de Witte TM
Zettl F
Béné MC
Westers TM
Source :: Leukemia & lymphoma [Leuk Lymphoma] 2013 Mar; Vol. 54 (3), pp. 472-5. Date of Electronic Publication: 2012 Sep 14.
Publication Year :: 2013
Abstract: An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.

Subjects :: Humans
International Agencies
Myelodysplastic Syndromes classification
Prognosis
Reproducibility of Results
Sensitivity and Specificity
Societies, Scientific
Flow Cytometry methods
Myelodysplastic Syndromes diagnosis
Myelodysplastic Syndromes therapy
Outcome Assessment, Health Care methods

Full Text Access

Tools